Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
IDegLira improves long-term health outcomes and reduces costs for diabetes patients
Last updated June 13, 2026
Key finding
HbA1c decreased by 0.6% (p<0.0001).
This study analyzed the long-term cost-effectiveness of IDegLira for treating type 2 diabetes in China, showing significant improvements in glycemic control and health outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Cohort
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study analyzed the long-term cost-effectiveness of IDegLira for treating type 2 diabetes in China, showing significant improvements in glycemic control and health outcomes.
Clinical relevance
This research highlights the effectiveness of IDegLira in managing type 2 diabetes, particularly in a population with poor glycemic control. By demonstrating significant reductions in HbA1c and the incidence of complications, this study supports the use of IDegLira as a viable treatment option that could improve patient outcomes and reduce healthcare costs associated with diabetes complications.
Keep in mind
The study may have limited generalizability to populations outside China. Potential unmeasured confounders could affect the outcomes. The analysis did not include long-term follow-up data beyond the initial study period.
Published in
Journal Reference
Publication details and source links for this paper.
Dunming X, Junling W, Lei Z, et al. Long-term cost-effectiveness of IDegLira versus GLP-1RA added to basal insulin regimen for patients with type 2 diabetes in China. PLOS ONE. 2025. doi:10.1371/journal.pone.0310497
Main Effects
HbA1c decreased by 0.6% (p<0.0001)
Systolic blood pressure decreased by 3.5 mmHg (p=0.0017)
Cumulative incidence of eye diseases decreased by up to 41.1%
Cumulative incidence of neuropathy decreased by 17.3%
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to IDegLira and BMI, Diabetic neuropathy incidence, Diabetic retinopathy incidence, and 11 more.
This study contributes evidence to
Primary intervention
IDegLira
Primary outcomes
- BMI
- Diabetic neuropathy incidence
- Diabetic retinopathy incidence
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
14
Evidence pairs
14
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
5
Related topics
14
Evidence pairs
1275
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 14 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Mass Index
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Diabetic neuropathy incidence
IDegLira → Diabetic neuropathy incidence
IDegLira → Diabetic neuropathy incidence
Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDiabetic retinopathy incidence
IDegLira → Diabetic retinopathy incidence
IDegLira → Diabetic retinopathy incidence
Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerIncidence of heart failure
IDegLira → Incidence of heart failure
IDegLira → Incidence of heart failure
Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerIncidence of macular edema
IDegLira → Incidence of macular edema
IDegLira → Incidence of macular edema
Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerIncidence of myocardial infarction
IDegLira → Incidence of myocardial infarction
IDegLira → Incidence of myocardial infarction
Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerRenal and urinary disorders incidence
IDegLira → Renal and urinary disorders incidence
IDegLira → Renal and urinary disorders incidence
Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- HbA1c decreased by 0.6% (p<0.0001)
- Systolic blood pressure decreased by 3.5 mmHg (p=0.0017)
- Cumulative incidence of eye diseases decreased by up to 41.1%
- Cumulative incidence of neuropathy decreased by 17.3%
Keep in Mind
- The study may have limited generalizability to populations outside China.
- Potential unmeasured confounders could affect the outcomes.
- The analysis did not include long-term follow-up data beyond the initial study period.
Between the Lines
- The study may have limited generalizability to populations outside China.
- Potential unmeasured confounders could affect the outcomes.
- The analysis did not include long-term follow-up data beyond the initial study period.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 47.1 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may affect body mass index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 47.1 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 20 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve cardiovascular outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Incidence of myocardial infarction
EvidenceScore™ Emerging | EvidenceScore™ 47.1 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists improve blood pressure?
Strong Evidence
GLP-1 Receptor Agonists may improve blood pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Systolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 47.1 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 47.1 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Liraglutide and Empagliflozin Improve Heart Function in DiabetesPhone-delivered diabetes education improves self-care behaviorsAzelnidipine improves blood pressure control in type 2 diabetes patientsBariatric surgery improves glucose homeostasis in type 2 diabetes.GLP-1 agonists reduce heart fat thickness in diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.